Peptide Screening: What Makes a High-Quality Screening Peptide?
Jump to section
Peptide screening plays a vital role in modern drug discovery, helping researchers rapidly explore target-ligand interactions, identify promising hits and progress the most promising candidates into optimisation and validation studies.
However, the reliability of these results depends heavily on the quality of the peptides used. In practice, even small inconsistencies in peptide synthesis, peptide purity, or preparation can have a substantial impact on experimental results. Variability at the peptide level can introduce noise, mask real signals, or result in misleading hits.
To generate reliable, reproducible data, peptides must therefore be sufficiently pure, soluble and stable under assay conditions. When these parameters are not properly controlled, they can undermine assay performance and reduce overall confidence in screening outcomes.
In this article, we look at each of these factors in detail and share practical tips to help you reduce variability and improve the reliability of your peptide screening, whether you are working with individual peptides or larger screening libraries.
Are you looking for a reliable source of high-quality peptides to support your discovery workflow?
Why Do Purity and Quality Thresholds Matter When Screening Peptides?
Not every peptide screening application demands the same purity, but every application is affected by it. Impurities carried through from synthesis can distort assay readouts, and the impact grows as peptides get longer or sequences get harder to make. Understanding where impurities come from, and how much peptide purity your particular assay actually needs, helps you avoid both misleading data and the unnecessary cost of over-specifying.
How Impurities Affect Screening Results
In a peptide screening assay, impurities are rarely inert. Truncated or deleted sequences, residual protecting groups, and non-peptide material left over from synthesis can each introduce background signal, compete with the intended peptide for its target, or make it harder to distinguish genuine biological activity from material-related artefacts1.
The risk is particularly acute in early screening, where a single concentration is often tested and there is no clean reference to flag that a result is being driven by something other than the target sequence. Impurities can also vary from batch to batch, so a peptide that performs one way in a pilot screen may behave differently when re-synthesised; a common and frustrating source of irreproducibility.
How Impurities Arise During Peptide Synthesis
Most screening peptides are made by solid-phase peptide synthesis (SPPS), in which the chain is assembled one residue at a time on a solid resin. In principle, if every coupling and deprotection step ran to completion, only the target sequence would result. In practice, no step is perfectly efficient, and the small fraction of chains that fail to react at a given cycle lead to truncated and deletion sequences2.
Other impurities form through side reactions: oxidation of residues such as methionine, deamidation of asparagine and glutamine, and dimerisation through reactive side chains such as the thiol of cysteine. Certain residues, including cysteine and histidine, are also prone to racemisation during coupling, which generates diastereomeric impurities that can be very difficult to separate from the target3.
The choice of coupling reagent and base are critical here, which is why synthesis conditions are optimised residue by residue rather than applied as a single generic protocol.
Why Longer Peptides Are Harder to Purify
Since impurities accumulate with every cycle, peptide length has a compounding effect on purity. Unlike classical organic synthesis, where intermediates are purified after each step, an SPPS peptide is typically purified only once, after the full chain is assembled and cleaved from the resin. Every deletion or side-product generated along the way is therefore carried through to the end.
The longer the sequence, the more cycles there are for impurities to form, and the more closely those impurities resemble the target, making them harder to resolve by chromatography. As a rough guide, reliable SPPS becomes progressively more challenging beyond around 50 residues, where accumulated deletions and on-resin aggregation of “difficult” sequences can interfere with further coupling4.
This is why two peptides specified at the same nominal purity can differ in how hard they were to synthesise, and why length and sequence difficulty, not just the final purity figure, are worth considering before making a purchase.
How We Ensure High Peptide Purity
Controlling impurities starts well before purification. At AltaBioscience, we use high-quality starting materials and coupling reagents, select protecting-group strategies that minimise racemisation, and adjust reaction conditions to suit each sequence.
We also make extensive use of capping during synthesis: any chain that fails to couple at a given cycle is “capped” so it cannot react further, which prevents the formation of deletion peptides and makes the remaining impurities easier to remove. Each peptide is then purified by reverse-phase HPLC and confirmed by HPLC and mass spectrometry, so that both its identity and its purity are verified against the intended design before it is released.
How Much Purity Does Your Application Need?
The right peptide purity level depends on what you are trying to learn. Early exploratory screening may tolerate lower purity peptides, particularly when the aim is to sample broad chemical diversity. However, once a promising hit is identified, higher purity and tighter consistency become more important for SAR studies, sequence refinement, and follow-up validation.
As a general guide:
- Lower purity peptides (e.g. ~70–80%) may be sufficient for early exploratory screening
- Higher purity peptides (>90–95%) are typically required for validation and follow-up studies
- Consistent QC documentation is essential at all stages to support traceability and interpretation
The goal isn’t always maximum purity, but fit-for-purpose quality that supports reliable screening decisions. To learn more about our peptide testing capacity, contact our technical team at info@altabioscience.com.
How Does Peptide Solubility Affect Assay Performance?
Even well-designed sequences can fail in peptide screening if they do not behave predictably in solution. Solubility is one of the most common practical obstacles in peptide screening, and also one of the most overlooked: a peptide that looks ideal on paper is of little use if it will not fully dissolve under assay conditions. As such, peptide solubility is recognised as one of the most critical parameters governing successful experimental performance5.
Why Poor Solubility Creates Problems in Peptide Screening Assays
When a peptide does not fully dissolve, the effective concentration in the assay is lower than intended. The immediate consequence is that activity is underestimated, meaning a genuine hit may be scored as weak or missed altogether.
Just as damaging is the effect on reproducibility: partially dissolved material gives inconsistent concentrations between replicates and between batches, so the same peptide can produce different readouts on different days. In a screen where decisions hinge on relative activity across many peptides, this kind of variability quietly undermines confidence in the entire dataset.
What Influences Peptide Solubility?
Solubility is governed largely by a peptide’s amino acid composition, which determines its net charge and overall hydrophobicity.
- Charge and isoelectric point: Peptides carry ionisable groups on their terminal residues and on acidic side chains (aspartate, glutamate) and basic side chains (lysine, arginine, histidine). A peptide is least soluble at its isoelectric point (pI): the pH at which its net charge is zero and there is little electrostatic repulsion to keep molecules apart. The further the working pH sits from the pI, the more net charge the peptide carries and the more readily it tends to dissolve. As a rough guide, peptides with more than around 25% charged residues are usually straightforward to dissolve in aqueous buffer.
- Hydrophobicity: Sequences rich in hydrophobic residues, such as tryptophan, phenylalanine, leucine, isoleucine, valine and methionine, are far more difficult to dissolve, and peptides with more than roughly 50% hydrophobic content may be only sparingly soluble in water, or effectively insoluble. These sequences are also the most prone to aggregation.
- Length and sequence composition: Longer peptides offer more opportunity for intramolecular interactions and aggregation. Recent studies using machine learning on synthesis datasets show that it is the overall amino acid composition, rather than the precise sequence order that is the major determinant of aggregation propensity during synthesis6.
Practical Ways to Improve Peptide Solubility
The good news is that most solubility problems can be anticipated from the sequence and managed, either by adjusting how the peptide is dissolved, or by designing the sequence with solubility in mind from the start.
Choose The Dissolution Conditions to Match the Peptide’s Charge
The pH of the solvent is the first lever. Basic peptides (pI above 7) generally dissolve more readily under mildly acidic conditions. A common starting point is a small amount of dilute acetic acid before diluting into buffer.
Acidic peptides (pI below 7) dissolve better under mildly basic conditions, such as a dilute ammonium bicarbonate solution. As peptides generally carry more charge at near-neutral pH (6–8) than under mildly acidic conditions, working away from the pI is usually the simplest first step.
Use Organic Co-Solvents For Hydrophobic Peptides
For sequences that resist aqueous buffers, a water-miscible organic solvent such as DMSO is often the most effective option: dissolve the peptide in a minimal volume of DMSO first, then dilute slowly into the working buffer.
This is where assay compatibility becomes an important factor. DMSO is well tolerated by many biochemical assays at low percentages, but organic solvents can be problematic in cell-based assays, where even modest concentrations may affect viability or introduce artefacts. As such, the final solvent level must stay within what the biological system can tolerate.
It is also worth noting that cysteine- and methionine-containing peptides can be unstable in DMSO, so DMF is often substituted for these sequences; and any co-solvent carried into the assay should be matched across all wells, including controls, so it does not itself become a source of variability.
Design The Sequence For Solubility Where The Application Allows
When a target region permits some flexibility, solubility can be engineered into the peptide rather than managed afterwards. Substitution of a problematic hydrophobic residue, or the addition of one or two charged or polar residues at a terminus can substantially improve solubility while preserving the functional core.
Terminal modifications and the placement of a solubilising tag are further options. These choices involve a trade-off against biological relevance, which is why they are best made in discussion with the synthesis team.
At AltaBioscience, we routinely assess sequences for likely solubility and aggregation issues before synthesis and can suggest modifications (substitutions, terminal changes, or solubilising tags) that improve handling without compromising the region you are trying to study.
Key takeaways: What is a Good Screening Peptide?
A good screening peptide is one that delivers reliable, reproducible data under real assay conditions. In practice, that comes down to three things:
1. Accurate Sequence and Reproducible Synthesis
A good screening peptide must faithfully represent the intended target region and be produced consistently at defined purity levels across batches. Even small sequence errors, synthesis inconsistencies, contamination, or batch-to-batch variation can lead to misleading results and off-target effects, particularly when comparing closely related variants or building structure–activity relationships.
2. Appropriate physicochemical properties
Charge, hydrophobicity, and overall sequence composition all influence how peptides behave in solution and within assay systems. Designing peptides with suitable properties helps reduce aggregation, improve solubility, and support more reliable readouts.
3. Compatibility with screening workflows
Even a high-quality peptide can introduce variability if it is awkward to handle or supplied in a format that adds preparation steps. The delivery format directly affects reproducibility and throughput, so it is worth choosing deliberately.
On that last point, the format in which peptides are supplied can significantly influence screening performance. Selecting the right one for your application reduces manual handling and keeps conditions consistent across every sample:
- Lyophilised peptides: Offer stability and flexibility, but require careful, consistent reconstitution to avoid variability.
- 96-well plate / 8 x 12 microtitre tray formats: Synthesis of up to 526 peptides in one batch dispensed in assay-ready formats to reduce pipetting errors and improve throughput in high-throughput screening environments.
- Peptide microarrays (glass slides) :Printed directly onto glass slides from the synthesis workflow, offering efficient arrangement of immobilised, high-availability peptides compatible with most imaging systems.
Choosing a format that aligns with your workflow helps reduce hands-on steps, limit variability, and enable reproducible, scalable screening from the outset.
Set Your Screening Campaign Up for Success From The Start
The difference between noisy data and meaningful insight often comes down to the details: peptide quality, consistency, and how well your workflow is supported from the outset. A peptide may be well-chosen biologically, but if it is difficult to dissolve, inconsistently prepared, or supplied in a format that adds unnecessary handling steps, the reliability of the screening data can suffer.
High-quality peptides, batch-to-batch consistency, robust QC documentation, and screening-ready formats all help reduce variability and support confident downstream decisions, from early hit identification to validation and SAR studies.
At AltaBioscience, we combine high-quality peptide synthesis with rigorous analytical control and flexible delivery formats, including lyophilised, pre-aliquoted, and plate-ready options designed for reliable, reproducible results. Whether you need a focused set of peptides or a larger screening library, we can help you.
Contact us today to explore how we can help you deliver consistent, high-quality results across your peptide screening campaigns.
References
- Bosc-Bierne, G. & Weller, M. G. Investigation of Impurities in Peptide Pools.Separations12, 36 (2025).
- Fields, G. B. & Noble, R. L. Solid phase peptide synthesisutilizing9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35, 161–214 (1990).
- Han, Y.,Albericio, F. & Barany, G. Occurrence and Minimization of Cysteine Racemization during Stepwise Solid-Phase Peptide Synthesis.J. Org. Chem. 62, 4307–4312 (1997).
- Paradís-Bas, M., Tulla-Puche, J. &Albericio, F. The road to the synthesis of “difficult peptides”.Chem. Soc. Rev. 45, 631–654 (2016).
- Oeller, M.et al.Sequence-based prediction of the intrinsic solubility of peptides containing non-natural amino acids. Nat. Commun. 14, 7475 (2023).
- Tamás, B., Alberts, M., Laino, T. &Hartrampf, N. Amino acid composition drives aggregation during peptide synthesis.Nature Chemistry 2026 18:4 18, 677–685 (2026).
- Fosgerau, K. & Hoffmann, T. Peptide therapeutics:current statusand future directions. Drug Discov. Today 20, 122–128 (2015).
